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Abstract:  
Muscle precursor cells (MPCs) are activated satellite cells capable of muscle fiber 
reconstruction. Therefore, autologous MPC transplantation is envisioned for the 
treatment of muscle diseases. However, the density of MPCs, as well as their 
proliferation and differentiation potential gradually decline with age. The goal of this 
research was to genetically modify human MPCs (hMPCs) to overexpress the 
peroxisome proliferator-activated receptor gamma coactivator (PGC-1α), a key 
regulator of exercise-mediated adaptation, and thereby to enhance early skeletal muscle 
formation and quality. We were able to confirm the sustained myogenic phenotype of 
the genetically modified hMPCs. While maintaining their viability and proliferation 
potential, PGC-1α modified hMPCs showed an enhanced myofiber formation capacity 
in vitro. Engineered muscle tissues were harvested 1, 2 and 4 weeks after subcutaneous 
injection of cell-collagen suspensions and histological analysis confirmed the earlier 
myotube formation in PGC-1α modified samples, predominantly of slow twitch 
myofibers. Increased contractile protein levels were detected by Western Blot. In 
summary, by genetically modifying hMPCs to overexpress PGC-1α we were able to 
promote early muscle fiber formation in vitro and in vivo, with an initial switch to slow 
type myofibers. Therefore, overexpressing PGC-1α is novel strategy to further enhance 
skeletal muscle tissue engineering. 
 
Key Words: human muscle precursor cells, differentiation, skeletal muscle tissue 
engineering, PGC-1α 
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INTRODUCTION 
Damage or loss of skeletal muscles is a major concern in many diseases. Autologous 
stem cell therapy is on the door step to successful clinical application and represents a 
novel treatment option for various muscle-related pathologies, including urinary 
incontinence1, vocal cord dysfunction2 and vesicoureteral reflux3. Satellite cells are 
quiescent cells, residing underneath the basal lamina of skeletal muscle fibers. They get 
activated after muscle tissue injury, turning into proliferating myoblasts, or muscle 
precursor cells (MPC). MPCs grant sufficient progeny for tissue repair4,5. Due to their 
potential to form new contractile myotubes, these cells are being investigated for muscle 
tissue engineering and reconstruction in the treatment of a variety of muscle disorders6-
9. 
Despite recent progress in the field of muscle tissue bioengineering, a decreased 
proliferative capacity of MPCs due to donor age remains the main shortcoming of this 
approach10-12. This challenge for autologous cell therapy may be addressed by exercise 
and/or therapeutic regulation of gene expression, which enhances the ability of MPCs to 
restore muscle fibers. The transcriptional coactivator peroxisome proliferator-activated 
receptor γ coactivator 1α (PGC-1α) is a key player in neuromuscular activity of skeletal 
muscle and regulates important exercise-mediated adaptations13,14. The PGC-1α 
expression in a muscle is proportional to the amount of exercise and protects skeletal 
muscle cells from atrophy, thereby, being beneficial for the cell survival15. It serves as a 
transcriptional coactivator of nuclear receptors and transcription factors, that play 
essential roles in the regulation of cellular differentiation, development and metabolism 
(carbohydrate, lipid, protein) of higher organisms15,16. Hence, PGC-1α is regulating the 
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mitochondrial biogenesis and is adapting the oxidative state in muscles14. The increase 
of PGC-1α levels goes along with a shift in the myofiber composition toward high-
endurance muscle fibers, that are capable of sustaining long-term contractions17. Slow-
twitch myofibers mostly use oxygen as electron acceptor to generate energy (ATP), 
which is gradually released for sustained, long contractions, resistant to fatigue18. 
Additionally, this high endurance muscle phenotype is characterized with pronounced 
tissue vascularization, increased mitochondria and myoglobin levels and enhanced 
import of glucose, lipids and lactate18. Similar changes are observed in adaptation to 
exercise, a process also mediated by PGC-1α. The therapeutic potential of PGC-1α in a 
metabolic optimization strategy is currently being investigated and highlights the 
importance of novel approaches for successful muscle tissue engineering19.  
Muscle reconstruction using human MPCs (hMPCs) is a promising and feasible therapy 
method. However, further improvements towards engineering of larger muscles, 
functional myofiber formation and increased integration into the host tissue are needed. 
Our project thus aimed at the generation and validation of a viral vector for ectopic 
expression of PGC-1α in hMPCs, in order to assess the therapeutic potential of in vivo 
bioengineering of skeletal muscle tissue in a mouse model. We hypothesize that initial 
overexpression of PGC-1α would improve the muscle cell survival, myofiber formation 
capacity and expression of muscle-specific proteins in the hMPCs. Moreover, it would 
induce a myofiber type switch into slow-type myofibers, which are highly desirable for 
sphincter muscle bioengineering. 
Copyright © 2017 Cognizant Communication Corporation 
 
 
 
 
 
CT-1627 Cell Transplantation early e-pub; provisional acceptance 01/03/2017         5 
 
MATERIALS AND METHODS  
Isolation and expansion of hMPCs 
Human muscle biopsies from the M. rectus abdominis were randomly collected upon 
ethical approval by the local swiss ethics institutions and after written informed consent 
of hospitalized patients undergoing abdominal surgery under general anesthesia. The 
samples were processed according to established protocols20. Briefly, each muscle 
biopsy was first minced and digested with collagenase Type I 0.2% (w/v) (Sigma) and 
dispase 0.4% (w/v) (Gibco). The enzymatic reaction was terminated with medium 
containing 10% FBS. Individual myofibers were then liberated by rigorous pipetting 
and filtered through a strainer with a pore size of 100 μm. After centrifugation the pellet 
was resuspended in culture medium and the pieces of muscle fibers and dissociated cells 
transferred into 35 mm dishes coated with collagen type I (1mg/ml) (BD) as a pre-
plating step. The culture medium consisted of DMEM/F12, 1% Penicillin/Streptomycin, 
18% FBS, 10 ng/ml hEGF (Sigma), 1 ng/ml hbFGF (Sigma), 10 μg/ml human insulin 
(Sigma) and 0.4 μg/ml dexamethasone (0.5 μM, Sigma) 20. After 24 h the supernatant 
containing non-adhered hMPCs was re-plated into dishes coated with collagen type I, in 
order to reduce the number of contaminating fibroblasts. 
 
Adenoviral transduction  
The AdEasy System was used as a tool for recombinant adenovirus generation. N-
terminal HA-tagged human PGC-1α was cloned into an adenoviral vector that codes for 
CMV promoter-driven green fluorescent protein (GFP). The expression of hPGC-1α 
was also under the control of a CMV promoter, thereby ensuring its robust, constitutive 
expression. Successful cloning was validated by sequencing, while viral infection and 
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expression of the fluorescent reported genes was monitored by visualizing GFP (for the 
PGC-1α expressing adenoviral vector). As control for viral infection a GFP adenovirus 
was used. The viral titer was increased through additional amplification step and 
quantified by fluorescent and bright field microscopy. The optimal multiplicity of 
infection (MOI) was measured by serial titrations of the viral vectors on hMPCs and 
simultaneous determination of GFP expressing cells by fluorescent microscopy, cell 
toxicity and cell viability. An optimal transduction protocol in culture media was 
established beforehand showing at least 90% cell survival. Finally, the transduced 
hMPCs were expanded for 2 days after infection and were s.c. injected in nude mice, 
upon ethical approval by the local ethics committees.  
 
Animal experimentation 
All animal experiments were approved by the swiss animal ethics committee 
(Veterinäramt Zürich, Lic. Nr.: 12-2012) and performed according to the animal ethics 
welfare law. A total of 24 nude mice (8 weeks old, female, Charles River) were divided 
in two groups (GFP and PGC-1α). For the in vivo experiments, the hMPCs were 
expanded to passage 3-4. Each sample contained 30x106 transduced hMPCs, which 
were gently mixed with 500 μl collagen type I carrier (final concentration: 2 mg/ml) 
(BD) and prepared for subcutaneous (s.c.) injection in the back of nude mice 21. Each 
animal received two bilateral s.c. injections each containing 30x106 hMPCs under 
general isoflurane anaesthesia and the engineered tissues were harvested after 1, 2, and 
4 weeks.  
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Cell characterization 
After expansion of hMPCs to passage 3 they were infected with the corresponding 
adenovirus and cultured for 2 days. The cells were characterized by fluorescence- 
activated cell sorting (FACS), using the following primary antibodies: anti-MyoD 
(1:100, BD), anti-MyHC (1:1, DSHB), anti-desmin (1:50, Sigma), anti-sarcomeric 
alpha-actinin (1:200, Sigma), anti-CD34 (1:100, BD) and anti-IgG Isotype control 
(1:100, Santa Cruise). Cy3 anti-mouse IgG (1:1000, Sigma) antibody was used as 
secondary antibody. A total of 50’000 events were registered by BD FACS Canto flow 
cytometer (BD Biosciences) immediately after labeling and the analysis was performed 
using FlowJo software v. 7.5 (Tree Star Inc.). All data are expressed as percentage of 
maximum (% Max). All measurements were performed with at least 3 different human 
biopsies. 
Additionally, the transduced hMPCs were cultured to 70-80% confluency, fixed with 
4% PFA for 10 min at room temperature, permeabilized with 0.5% TritonX-100 
(Sigma) for 7 min, blocked for 30 min (5% BSA + 0.1% TritonX-100 in PBS), and 
finally stained with anti-desmin (1:50, Sigma), anti-sarcomeric α-actinin (1:200, 
Sigma), anti-CD34 (negative control) (1:100, BD) over night at 4 oC. After washing 
with PBS, the cells were incubated with Cy3 anti-mouse IgG secondary antibody 
(1:1000, Sigma) and DAPI (1:100, Sigma) for 1h at room temperature, washed again 
and finally mounted (Dako). Images were acquired with Leica-Imager Type DM6000B 
at exposures normalized to unstained controls (secondary antibody and DAPI only). 
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Fiber formation assay 
Differentiation of hMPCs into myofibers in vitro was performed as previously reported 
(fiber formation assay)20. Briefly, hMPCs were grown to 50% confluency in culture 
medium and afterwards in differentiation medium (10% FBS) for 7-10 days until 
myofibers formed. The myofibers were fixed with ice-cold methanol (7 min), stained 
with Giemsa (1:20, 45-60 min) and air-dried. Five high-power-fields (HPF, 10x) were 
obtained per condition from cell samples from 4 patients` biopsies and the results were 
expressed as number of myofibers/HPF, number of nuclei/myofiber, and number of 
nuclei/HPF. The fusion rate was calculated by dividing the number of nuclei/myofiber 
by the number of nuclei/HPF (%). A total n=4x5HPF (20x) were analyzed. The imaging 
software “ImageJ for microscopy“ was used for data assessment.  
 
Cell viability and proliferation 
In all cases, cell numbers and viability were confirmed by trypan blue staining after 
trypsinization. To evaluate proliferation and viability of the infected cells at different 
time points, hMPCs were cultured for 6 days. The cell proliferation reagent WST-1 
(Roche) was used according to the manufacturer’s protocol. For further confirmation of 
cell viability hMPCs were stained with 10 μM CellTrace Calcein Red-Orange, AM 
(Life Technologies) for 30 min at 37 °C. Viable cells were detected using a fluorescence 
microscope. All measurements were performed in duplicates of at least 3 different 
human biopsies. 
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Immuno-/Histological assessment 
The harvested neoformed graft-derived tissues were embedded in cryo-preservative 
(OCT embedding medium, Cell Path) immediately after isolation. Cryostat sections 
were prepared (10 μm) and further processed. Haematoxylin and eosin (H&E) (Sigma) 
staining was performed according to the manufacturer’s protocol. For 
immunohistological analysis the tissues were fixed with ice-cold MeOH (60 min), 
permeabilized (0.5% TritonX-100, 20 min), blocked for 30 min (5% BSA + 0.1% 
TritonX-100 in PBS), and finally stained with anti-MyHC (1:2, DSHB) over night at 4 
oC. After washing with PBS, the tissues were incubated with Cy3 anti-mouse IgG 
secondary antibody (1:1000, Sigma) and DAPI (1:100, Sigma) for 1 h at room 
temperature, washed again and finally mounted (Dako). Images were acquired with 
Leica-Imager Type DM6000B at exposures normalized to unstained controls (secondary 
antibody and DAPI only). 
 
Real-time PCR and CK assay 
For analysis of PGC-1α downstream regulated genes (by RTPCR) and creatine kinase 
(CK) levels (measured using the Cobas c111 system (Roche Diagnostics) according to 
manufacturer’s protocol), the cells were cultured for 2 days after infection and then 
transferred to differentiation medium for 9 h, or until day 6, respectively, and finally 
harvested for further assessments. For gene analysis of tissue, the harvested tissues were 
pulverized in liquid nitrogen and suspended in RNA lysis buffer. Total RNA was 
isolated for both, cells and tissues, using the SV Total RNA Isolation System kit 
Copyright © 2017 Cognizant Communication Corporation 
 
 
 
 
 
CT-1627 Cell Transplantation early e-pub; provisional acceptance 01/03/2017         
10 
 
(Promega) according to the manufacturer's protocol, which includes a DNase digestion. 
RNA was reverse transcribed with random primers (High-Capacity cDNA reverse 
transcription, Life Technologies). Pre-designed primers for human PPARGC1 
(Hs01016719_m1), MYH1 (Hs00428600_m1), desmin (Hs00157258_m1) and VEGF 
(Hs00900055_m1) were purchased from Life Technologies. Further primers were 
purchased from Microsynth: hCox5b (fwd primer: ATG GCT TCA AGG TTA CTT 
CGC, rev primer: CCC TTT GGG GCC AGT ACA TT), hCycS (fwd primer: CTT 
TGG GCG GAA GAC AGG TC, rev primer: TTA TTG GCG GCT GTG TAA GAG), 
hERRα (fwd primer: AGG GTT CCT CGG AGA CAG AG, rev primer: TCA CAG 
GAT GCC ACA CCA TAG), hPGC-1α (fwd primer: TCT GAG TCT GTA TGG AGT 
GAC AT, rev primer: CCA AGT CGT TCA CAT CTA GTT CA), and hTBP (fwd 
primer: CCC GAA ACG CCG AAT ATA ATC C, rev primer: AAT CAG TGC CGT 
GGT TCG TG). 18S rRNA (4319413E) was used to normalize cDNA concentrations. 
For quantification, the expression of each gene was normalized to the 18S, or TBP 
expression in the corresponding sample. The entire experiment was repeated at least 
three times and samples were analyzed in triplicates. 
 
Gel electrophoresis and immunoblotting 
In summary, tissues were pulverized in liquid nitrogen with a mortar/pestle and 
suspended in lysis buffer supplemented with a protease inhibitor cocktail (Sigma). 
Afterwards, the samples were centrifuged for 20 min at 13,000 rpm, and the supernatant 
was collected for protein determination. The total protein was measured with the BCA 
Protein Assay Kit (Thermo Scientific) and protein lysate (30-50 μg) was loaded on a 
Copyright © 2017 Cognizant Communication Corporation 
 
 
 
 
 
CT-1627 Cell Transplantation early e-pub; provisional acceptance 01/03/2017         
11 
 
10% or 12% gel (Bio-Rad). Western blot was performed according to the 
manufacturer’s protocol. After the separated proteins were electro-transferred onto 
PVDF membrane (Immobilion-P; Millipore), the latter was incubated with a primary 
antibody at 4 °C overnight in TBS, 0.1% Tween-20 and 5% non-fat dry milk. The 
primary antibodies used were anti-MyHC1 (1:5, DSHB), anti-MyHC (1:1, DSHB), anti-
desmin (1:50, Sigma), anti-PGC-1α (1:1000, Calbiochem), anti-sarcomeric α-actinin 
(1:2000, Sigma), anti-GAPDH (1:2500, Sigma), and α-tubulin (1:2000, Bioconcept). 
Finally, the membranes were washed in TBS with 0.1% Tween-20 for 30 min and 
incubated with the appropriate HRP-conjugated secondary antibody (Amersham 
Pharmacia Biotech) for 1 h. The signals were detected by the ECL method (ECL-Kit, 
Amersham). The data were analyzed by Image Studio Lite (Li-Cor) software and 
represented as protein expression relative to GAPDH. 
 
Statistics 
For statistical analysis IBM SPSS v22.0 (SPSS Inc,) was used and graphics were drawn 
with GraphPad Prism v5.04 (GraphPad Software, Inc.). All data were analyzed by 
Student’s t-tests for paired samples or one-way ANOVA with Bonferroni or LSD post-
hoc analysis (p<0.05 was considered significant). All presented data are expressed as 
means with corresponding standard error of the mean (±SEM). 
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RESULTS 
Generation and establishment of genetically modified hMPC 
Adenoviral constructs containing hPGC-1α, or GFP only, were successfully generated 
and amplified for further use in hMPCs. The expression of each gene was designed to 
be under the control of a CMV promoter in order to assure robust expression of the 
transgene. The transduction efficiency was confirmed by fluorescent imaging, as both 
constructs contain a green fluorophore, expressed under a separate CMV promoter 
(Fig.1. A, green). The constructs enabled detection of transduced cells both prior to 
transplantation for assessing the cell transduction efficiency, and afterwards, on 
engineered muscle sections. The safety of the viral infection was visualized by a cell 
viability assay (CaAM) (Fig. 1 A, red) and further confirmed by Trypan-blue staining 
for distinction of live/dead cells (Fig. 1 B), showing no significant differences between 
infected (GFP (90.5±1.97, n=6), PGC-1α (88.16±5.32, n=6)) and wild type (WT, 
89.00±3.01, n=8) cells. The proliferation capacity of the WT, GFP- and PGC-1α-
overexpressing hMPCs was determined by a cell proliferation assay (WST-1) over 6 
days culturing after transduction, showing no significant variations between the 
different groups (Fig. 1 C, at 6 days: WT (2.77±0.18, n=6); GFP (3.12±0.19, n=9); 
PGC-1α (2.59±0.29, n=12)). Importantly, the designed adenoviruses did not affect the 
expression of specific muscle protein markers (sarcomeric α-actinin and desmin), as 
detected by immunofluorescence imaging of hMPCs (Fig. 2 A) and FACS (Fig. 2 B) 
under culturing conditions. The latter also showed expression of specific well-described 
markers for characterization of activated hMPCs4, as well as a significant shift in GFP 
expression levels in both transgenic groups, compared to uninfected WT cells (Fig. 2 
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C). These results confirm the successful adenoviral transduction of hMPCs and their 
maintained cell phenotype. 
 
PGC-1α overexpression facilitates differentiation of hMPCs into myotubes in vitro 
To directly assess the role of PGC-1α in myofiber formation, an in vitro hMPCs 
differentiation experiment was performed. A Fiber Formation Assay22 with 
untransduced (WT), GFP- and PGC-1α-infected cells revealed an increased fusion rate 
in PGC-1α overexpressing myoblasts (Fig. 3 A and B, n=4x5 HPF). The participation of 
transduced GFP-positive cells in the myotube formation could be visualized by 
fluorescent microscopy (Fig. 3 A, second row, fluorescence). The facilitated initial 
differentiation of the PGC-1α overexpressing cells was further confirmed by Western 
Blot (Fig. 3 C) where elevated desmin levels were detected already at day 2 after 
infection after 9h of differentiation.  
The induction of differentiation goes hand in hand with an increase in metabolic activity 
(ATP consumption). To analyze this process, the intra- and extra-cellular creatine 
kinase (iCK and eCK) levels were measured 2 and 6 days after adenoviral infection and 
initiation of differentiation The iCK levels were significantly increased in PGC-1α 
infected cells at day 2 compared to GFP-infected cells (p<0.001) (Fig. 3 D). At day 6 an 
overall increase in iCK levels in all 3 groups, concomitant with the induced 
differentiation could be seen (Fig. 3 D). Importantly, an increase in eCK levels is often 
associated with muscle damage, cell death and membrane disruption23. Our results show 
that the viral infection did not affect the viability and integrity of hMPCs and that the 
eCK levels remained low 2 and 6 days after infection (Fig. 3 E).  
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Efficient elevation of PGC‐1α and downstream regulated genes using viral vectors 
in hMPCs 
Functionality of the expressed PGC-1α protein was validated by determination of well-
described target genes of the coactivator in muscle cells. As expected, the introduction 
of the PGC-1α viral vector specifically elevated the corresponding gene expression level 
after 2 days (p<0.01) and 6 days (p<0.0001) after inducing cell differentiation (Fig. 3 F 
and G). The bioactivity of the construct was furthermore confirmed after 2 and 6 days, 
respectively, by the induction of its target genes cytochrome c oxidase subunit 5b 
(Cox5b) (p<0.05, p<0.01), cytochrome c (CycS) (p<0.001, p<0.001) and estrogen-
related receptor α (ERR α) (p<0.0001, p<0.05), compared to the control cells infected 
with GFP and untransduced hMPCs (WT) (Fig. 3 H and I). These data confirm the 
efficiency of the presented PGC-1α adenoviral construct for genetic modification of 
hMPCs.  
 
PGC-1α triggers early myotube formation in vivo 
Encouraged by our in vitro observations, we further evaluated the capability of 
transduced hMPCs to form ectopic muscle tissue in vivo. The tissues formed by 
subcutaneously injected hMPCs (transduced with GFP or PGC-1α) were harvested after 
1, 2 and 4 weeks for analysis. The weight of the collected tissues did not differ 
significantly between the two groups (GFP and PGC-1α: 114.9±18.73mg, 
88.47±15.96mg (p=0.3021); 39±5.84 mg, 42.33±4.76mg (p=0.6814), 19.44±2.33mg, 
22.94±2.28mg (p=0.3219) at 1, 2 and 4 weeks, respectively, data not shown), although a 
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tendency for visually smaller PGC-1α tissues at 1 week was observed, concomitant with 
the enhanced differentiation (Fig. 4 A). The constant tissue volume decrease over time 
in the ex situ model due to myofiber formation and simultaneous collagen remodeling 
has previously been reported21. Histological assessment via H&E staining of the 
engineered tissue revealed earlier formation of myotubes in the PGC-1α samples 
(already at week 1) (Fig. 4 C, black arrows). This was further confirmed by 
immunohistological staining of the samples for MyHC, a marker for muscle 
differentiation and maturation, displaying an increased signal (Cy3, red) in the PGC-1α 
transduced tissues and more organized structures (myotubes) (Fig. 4 D, white 
arrowheads). The typical red color of slow twitch oxidative type I myofibers 17 could be 
detected macroscopically after tissue pulverization with liquid nitrogen in the PGC-1α 
samples, but not in the control GFP samples after 1 week (Fig. 4 B). This was 
concomitant with an initial significant increase in VEGF-A gene levels (p<0.0001) in 
the harvested PGC-1α overexpressing tissues (Fig. 5 A). The PGC-1α overexpression 
was confirmed by RTPCR (Fig. 5 B, p=0.009). The earlier differentiation was further 
confirmed by an increase in desmin (p=0.047) and MyHC1 (p=0.024) gene expression 
in the PGC-1α infected samples, while GFP-infected samples did not show expression 
at week 1 (Fig. 5 C and D, n=3-5). In line with this results, at protein level, PGC-1α 
overexpressing engineered muscle tissue also indicated an increase in relative 
expression levels of desmin (Fig. 5 E, 2.36±1.32, n=6) and MyHC1 (Fig. 5 F, 
2.24±0.67, n=4) at week 1, compared to GFP samples. An increase in the expression of 
MyHC protein over time could be observed (Fig. 5 G, 2.5±0.96 at 4.week, n=4), leading 
to a suggestion for a PGC-1α-induced shift towards MyHC1 type myofibers at 1 week 
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(Fig. 5 H). Based on the findings above, PGC-1α overexpressing hMPCs hold promise 
for the enhanced repair of skeletal muscle tissue due to their capacity to speed up 
myofiber formation, with an initial shift to oxidative type I myofibers.  
Discussion 
Muscle tissue bioengineering has made substantial progress over the last decade, 
allowing us to grow functional muscle tissue21,24. Subcutaneous implantation of 
myoblasts may have a range of useful applications, from the study of myogenesis to the 
delivery of gene products24. Nevertheless, there are still substantial limitations in size 
and quality of the engineered constructs. Additionally, drugs including testosterone, 
growth hormone, leptin, myostatin inhibitors, creatine and vitamin D have been 
successfully used to support muscle strength and growth25. Yet, there are safety 
concerns for their long-term application and, therefore, more investigations are required 
in order to minimize their adverse effects. Another possible solution for rebuilding 
muscle tissues is cell therapy using satellite cells. The induced expression of several 
factors in MPCs has extensively been studied, mostly to obtain enhanced cell viability 
and proliferation, or to prevent apoptosis and induce angiogenesis, or to induce gap-
junction formation against cardiac arrhythmias26. 
Many muscle disorders are associated with skeletal muscle inactivity and exercise is an 
exceptional therapeutic mediation for many disease conditions27. Although the exact 
mechanisms mediating these healing effects still remain elusive, several pathways have 
been proposed28. While resistance training combined with adequate nutrition remains 
the most effective intervention for diminishing the functional decline in muscles, there 
is a certain age-linked barrier to obtaining full benefits from this therapy25. 
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A promising molecule controlling skeletal muscle metabolism with potential therapeutic 
effect has been identified14. PGC-1α is a known and potent transcription coactivator for 
nuclear receptors and other transcription factors. It is expressed in skeletal muscles and 
is a powerful master regulator of mitochondrial bio-genesis29. Interestingly, PGC-1α has 
been shown to increase the expression of myofiber type I fibrillar proteins by co-
activating the myocyte enhancer factor 2 (Mef2) transcription factors, thereby 
coordinating the expression of both metabolic and contractile properties of type I 
myofibers17. These findings make PGC-1α a good candidate for targeted regulation of 
skeletal muscle cell metabolism and plasticity in the myofiber formation process, and, 
therefore, we decided to research its applicability for the bioengineering of improved 
muscle tissues.  
The ultimate goal in skeletal muscle tissue engineering is the construction of a 
functional tissue of a desired myofiber type. Interested in sphincter muscle 
bioengineering, we aimed at improving the regenerative potential of human MPCs by 
inducing PGC-1α overexpression through adenoviral gene delivery. By overexpressing 
PGC-1α in hMPCs we targeted a major crossroad of intracellular pathways, affecting 
cell metabolism (mitochondrial activity upregulation) and, simultaneously, enhancing 
the early expression of contractile proteins (MyHC1, desmin) and secretory factors 
(VEGF-A), thereby facilitating the process of skeletal muscle bioengineering. Our data 
showed feasibility of viral overexpression of PGC‐1α with desired phenotypic changes 
in the ectopic muscle but importantly without detrimental side effects on hMPC 
viability and differentiation in vivo and in vitro. We acknowledge that WST-1 
measurement is dependent upon mitochondrial function and PGC-1α might mask the 
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possible lack of proliferation in the infected cells. However, we visualized the cell 
viability by CaAM assay and quantified it by trypan blue staining, without observing 
any detrimental effects upon PGC-1α viral infection. 
The bioactivity of PGC-1α was confirmed by significantly enhanced expression of 
PGC-1α downstream targets, proving the functional efficiency of the presented 
construct. Some supporting evidence suggests an increased expression of mitochondrial 
and other metabolic genes as a plausible mechanism for rescuing a damaged muscle27. 
Therefore, the demonstrated increase in PGC-1α downstream mitochondrial targets was 
a key milestone for further in vitro and in vivo studies. 
A crucial role in the process of forming new muscle tissue is played by the capacity of 
myoblasts to differentiate into myotubes/myofibers and a sustained energy metabolism. 
Our genetically modified hMPCs showed a significantly increased fusion rate, in 
parallel with an enhanced energy metabolism, depicted by iCK levels and mitochondrial 
gene level analysis. Given the low iCK levels in myoblasts and their increase with 
myotube formation, our results indicate that viral overexpression of PGC-1α drives 
higher iCK expression, possibly due to a faster differentiation process. Moreover, 
elevated desmin protein expression was detected 2 days after the adenoviral infection, 
showing the early appearance of sarcomeric architecture. Consistent with the observed 
facilitated in vitro differentiation, the ectopically formed skeletal muscle tissue with 
PGC-1α overexpression revealed myotube formation and increased expression of 
contractile proteins (desmin and MyHC1) already after 1 week, indicating facilitated 
differentiation. Interestingly, this strong effect was reduced at later time points. 
However, PGC-1α modified samples expressed higher levels of general MyHC with an 
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increase over time, when compared to GFP samples, while there was higher MyHC1 
(slow twitch) protein expression at one week. These data indicate a possible initial shift 
towards slow type myofibers. Related gene-delivery studies suggest that overexpression 
of certain factors (e.g. VEGF) may be beneficial at the time of cell transplantation, and 
their transient effect may prevent the risk of malignancy formations30,31.  
Vascularization of the bioengineered tissue is the bottle-neck of many approaches. 
Importantly, PGC-1α overexpressing tissues showed enhanced VEGF-A gene levels. 
Secretion of various effectors by the injected hMPCs may also contribute to 
optimization of the regenerative process (e.g. increased neovascularization)21,32. 
Moreover, PGC-1α has been demonstrated to stimulate angiogenesis in skeletal muscle 
by inducing the release of key factors, including VEGF, in cultured muscle cells and 
skeletal muscle in vivo33. Furthermore, PGC-1α seems to have led to overexpression of 
VEGF-A, thereby, probably inducing early neo-vascularization and counteracting 
necrosis after implantation, possibly leading to improved cell/tissue survival and better 
long term survival. In line with our in vivo observations, others have shown, that an 
increased VEGF release in a hypoxic environment leads to enhanced differentiation34. 
This could explain the observed increase in contractile MyHC protein and myofiber 
formation in PGC-1α engineered tissues, when compared to the corresponding GFP 
samples.  
Whether the accelerated differentiation seen in this research using an ex situ model 
really leads to functional improvement during regeneration has to be validated using 
i.m. injection of the modified cells. However, the use of ectopic model for muscle tissue 
engineering also brings along valuable information about the formation of muscle fibers 
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in a non-myogenic environment, as it might be in the patients, e.g. scar tissue. 
Considering these facts, the optimal model to study skeletal muscle regeneration would 
be to inject the cells in injured muscles. Further, the use of viral gene delivery for 
clinical applications is still associated with several drawbacks35. We acknowledge that 
the choice of the adenoviral delivery method might not be the most suitable one. For a 
clinical set up, we would suggest a non-viral gene delivery method. We further 
acknowledge a possible immune reaction from the mice we chose, although no 
detrimental effects were detected in the engineered tissues. Still this model sets a 
significant milestone towards the possible engineering of improved muscle tissue of a 
desired myofiber type.  
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FIGURE LEGENDS 
Figure 1. PGC-1α adenoviral infection without adverse effects on hMPC. The 
successful adenoviral transduction of hMPCs with GFP and PGC-1α (A, green) did not 
affect the cell viability, as shown by CaAM assay (A, red). This was further confirmed 
by Trypan Blue staining of live/dead cells (B). Proliferation rate also did not differ 
between the wild type (WT) non-infected cells and the infected hMPCs (C). Scale bar: 
50μm 
Figure 2. Adenoviral infection did not change the hMPC phenotype. The expression 
of typical muscle markers (Cy3-red) in the infected cells (green) was confirmed by 
Immunocytochemistry. Nuclei were stained with DAPI (blue) (A). The hMPCs were 
analyzed by FACS for expression of various muscle marker proteins (B) and the 
successful transduction was confirmed by a shift in FITC signal (C). Scale bar: 25μm  
Figure 3. PGC-1α overexpressing hMPCs differentiate faster into myotubes in 
vitro. Fiber formation assay 22 and fluorescent microscopy revealed successful myotube 
formation in WT hMPCs and infected cells (green fluorescence) respectively (A), with 
an increased fusion rate in PGC-1α overexpressing cells (B). Two days after infection, 
PGC-1α overexpressing hMPCs displayed enhanced desmin protein levels (C). 
Intracellular CK (iCK) levels were significantly increased 2 days after PGC-1α infection 
(D), whereas extracellular (eCK) levels remained unaffected (E). An overall increase in 
iCK levels was observed 6 days after inducing differentiation of the hMPCs (D) and 
eCK remained unchanged (E). PGC-1α gene expression levels were upregulated in 
hMPCs, infected with PGC-1α adenovirus after 2 (F) and 6 days (G) post infection, 
compared to GFP and WT controls. PGC‐1α downstream genes (hCox5b; hCycS; 
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hERRα) were upregulated in hMPCs transduced with PGC‐1α, respectively (H, I). Data 
are presented as gene expression relative to hTBP, using the ddCt method. Scale bar: 
50μm 
Figure 4. Engineered muscle formation is enhanced by overexpression of PGC-1α 
in hMPCs. hMPCs transduced with PGC-1α, or control GFP adenovirus were injected 
subcutaneously on both sides of the back of nude mice. The harvested tissue was 
visualized macroscopically at 1 week at the subcutaneous tissue (A). The typical red 
color of oxidative type I myofibers was enriched in PGC-1α samples, compared to GFP 
controls (samples powderized with liquid nitrogen) (B). The process of successful 
myofiber formation was visualized over 4 weeks with H&E staining (C), revealing an 
increased early myotube formation in PGC-1α overexpressing samples (black arrows). 
Tibialis anterior (TA) was used as native control for muscle fiber formation. The 
increased differentiation capacity of PGC-1α transgenic hMPCs at early time points (1 
week) was also envisioned by immunostaining for MyHC (Cy3, red) of the ex situ 
engineered muscle fibers (green) (DAPI, blue) (D). White scale bar: 50 μm, black scale 
bar: 0.5cm 
Figure 5. Gene and protein expression in ex situ bioengineered muscle tissues, 
overexpressing PGC-1α. Gradual increase of VEGF-A gene expression levels was 
shown by RTPCR (A). PGC-1α gene overexpression was confirmed (B). Desmin and 
MyHC1 gene expression levels (relative to 18S) were increased in PGC-1α 
overexpressing tissues (C, D). The enhanced differentiation in PGC-1α overexpressing 
tissues could also be shown by increased contractile protein expression levels in the 
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corresponding bioengineered tissues (E-G). The ratio of MyHC1 to general MyHC 
showed an initial switch to oxidative type I myofibers (H). 
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